Not surprisingly, therefore, considering also the FXa inhibitory effects of TFPI, Oltrona et al. [57] found that systemic administration of recombinant TFPI led to a marked prolongation in PT, suggesting that recombinant TFPI at doses effective in preventing arterial thrombosis might be associated with a substantial risk of bleeding. This evidence concerns the gene TFPI and deep vein thrombosis.